Health ❯ Healthcare ❯ Vaccines

COVID-19

Moderna mRNA Technology Booster Shots FDA Approvals Public Health Policy Vaccine Development Vaccine Distribution Pfizer FDA Approval Vaccine Availability Vaccine Safety Pfizer-BioNTech Vaccine Controversies Variants mRNA Vaccines Licensure RSV Vaccines Vaccine Misinformation Adverse Events Vaccine Approval Vaccine Approval Process Nuvaxovid Side Effects HIV Vaccine Market Children and Pregnant Women Pharmacy Services Treatment Recommendations Vaccine Advocacy Pharmaceuticals Procurement Regulatory Approval Approval Standards Clinical Trials Regulatory Guidance Approval Process Immunogenicity Data Vaccine Advisory Panels Public Health FDA Regulations Regulations 2025-2026 Vaccines Chicago Advisory Committees Spikevax Co-administration of Vaccines Novavax Operation Warp Speed Access Vaccine Efficacy Vaccine Skepticism SARS-CoV-2 Variants Pfizer and BioNTech Updates Vaccine Policy Changes Insurance Coverage High-Risk Populations

FDA Approves XFG-Targeted COVID Vaccines for Older and High‑Risk Americans

Manufacturers are shipping doses now while formal CDC season guidance is unresolved, leaving access and coverage rules to states and providers.

FDA Advisers Recommend XFG as Target for 2026–2027 COVID-19 Vaccines

Moderna Beats Q1 Forecast as Overseas COVID Shot Sales Rebound

Pfizer and BioNTech Halt U.S. COVID Vaccine Trial for 50–64-Year-Olds Over Slow Enrollment

Moderna Trims 2025 Forecast as Q3 Loss Narrows and Revenue Beats

States Restore Broad COVID-19 Shot Access as Pharmacies Roll Out Patchwork Policies

Pharmacies Curtail Covid Vaccines in 16 States as Confusion Over Federal Guidance Disrupts Access

Greene Urges DOJ to Drop Charges Against Surgeon on Trial for COVID-19 Vaccine Fraud

FDA Approves Moderna’s mNEXSPIKE for High-Risk Populations